HRONIC MYELOGENOUS leukemia (CML) is a C malignant disorder of the human hematopoietic stem cell characterized by the Philadelphia chromosome (Ph')' and, at the molecular level, juxtaposition of 5' coding sequences of the major breakpoint cluster region (bcr) gene on chromosome 22 and 3' coding sequences for the c-abl gene on chromosome 9.2 There is a marked increase in immature hematopoietic progenitors of malignant origin in bone marrow and blood of CML patient^.^ Despite the marked expansion of the malignant hematopoietic stem cell clone, presumed benign Ph'-negative hematopoietic stem cells may coexist with the malignant Ph'-positive hematopoietic stem cells in some patients with CML. 4 . ' Discriminating characteristics between benign and malignant Ph'-positive hematopoietic stem cells have not been described. Normal human hematopoietic stem cells capable of complete myeloid and lymphoid reconstitution of lethally irradiated hosts are present in the CD34' fraction of human bone marrow.' Standard culture systems using semisolid media detect colony-forming cells, but fail to support the growth of more primitive uncommitted progenitor The long-term bone marrow culture (LTBMC) system described by Dexter et all3 supports proliferation of primitive human hematopoietic progenitor cells for at least 12 weeks. Cells capable of initiating LTJ3MC (LTBMC-IC) are lineage-negative,'0311 CD34', and do not express HLA-~~1 0 , 1 2 , 1 4 or CD33 antigens." These primitive progenitors contain only small numbers of committed hematopoietic progenitor^,'^^'^^'^ but can proliferate and differentiate in vitro in close contact with human bone marrow-derived stromal layer^.'^^'^'^ In this report, we examine the phenotypic characteristics of benign and malignant primitive hematopoietic progenitors from CML bone marrow. We demonstrate that benign Ph'-negative progenitors from some CML patients can be phenotypically identified in the bone marrow of Ph'-positive CML patients. These benign progenitors do not express cell surface antigens of committed myeloid or lymphoid lineage, express high levels of CD34 antigens, and fail to express HLA-DR antigens. In contrast, coexistent malignant primitive progenitors exhibiting the characteristic Ph' and bcrlabl gene rearrangement do express HLA-DR antigens. 
MATERIALS AND METHODS

Bone Marrow Samples
Bone marrow was obtained from the posterior iliac crest of seven chronic-phase CML patients and 10 healthy young volunteers after informed consent. Patient characteristics are summarized in Table  1 .
Bone marrow mononuclear cells (BMMNC) were obtained after Ficoll-hypaque separation (specific gravity, 1.077). BMMNC from patients 5 to 7 were purified further in an initial counterflow elutriation step.I4 BMMNC were resuspended in Iscove's modified Dulbecco's medium (IMDM) supplemented with 5% fetal calf serum (FCS) and 0.01% EDTA. The cells were injected into an elutriator system with standard separation chamber (Beckman Instruments, Palo Alto, CA) primed with IMDM-FCS-EDTA. Rotor speed and temperature were maintained at 1,950 rpm and 10°C. After loading, 200 mL of effluent was collected at a flow rate of 8 mL/min, and 100 mL was collected at a flow rate of 12 mL/min. The rotor was then stopped and the remaining BMMNC flushed from the separation chamber.
1004
VERFAlLLlE ET AL (Fig IC) ." These windows were chosen on the basis of the fluorescence pattern of control samples labeled with mouse IgG (Sigma, St Louis, MO), FITC-conjugated goat F(ab)'* anti-mouse IgG, and finally mouse IgGZ-PE antibodies (Fig 1B) . Less than 0.1% residual cells labeled with low levels of lineage-specific mouse IgG used in the lineage-negative immunomagnetic depletion step were included in the CD34+ fraction. Analysis of sorted cells demonstrated that 97% or more of DR-cells expressed 0 3 4 antigens and 2% or less expressed HLA-DR antigens, while DR+ cells contained 95% or more cells expressing both CD34 and HLA-DR antigens. Although both DR-and DR+ cells were sorted using the same lightscatter gates, the lightscatter profiles from reanalyzed sorted cells indicated that DR-cells are slightly smaller (very low forward scatter) than those sorted in the DR+ fraction (low forward scatter).
Short-Term Methylcellulose Cultures
DR-and DR' cells (1@ cellslml) were plated in clonogenic methylcellulose assay as previously described," containing 3 IU recombinant erythropoietin (Amgen, Thousand Oaks, CA) and 10% conditioned media from the bladder carcinoma cell line 5637. Cultures were incubated in a humidified atmosphere at 37°C and 5% CO, and assessed for the presence of colony-forming cells 
Cytogenetic Analysis of Plucked Colonies
Colonies plucked from short-term methylcellulose cultures of cells harvested from adherent and nonadherent fractions of LTBMC initiated with CML DR-and DR' progenitors, respectively, were pooled in IMDM with 20% FCS and were subjected to a 1.5-hour colcemid incubation followed by lysis with hypotonic KCI and fixation in acid/alcohol as previously described. In each of seven cases described, metaphases were analyzed after QFQ or GTG banding.I6
Polymerase Chain Reaction (PCR) Amplification of the bcrlabl mRNA
Colonies arising from adherent and nonadherent cells of LT-BMC initiated with CML DR-and DR' cells, respectively, were plucked from methylcellulose cultures using a Pasteur pipette and frozen at -70°C in 100 pL phosphate-buffered saline (PBS).
Total cellular RNA was extracted from thawed colonies according to the method of Chomczynski and Sacchi." To protect the RNA, guanidinium was added before cell disruption. Pelleted cells were lysed in the presence of guanidinium thiocyanate, sodium citrate, and sarcosyl, and RNA was extracted with phenol and chloroform/isoamyl alcohol. RNA was precipitated using glycogen as a carrier.
Oligonucleotide primers and probes were prepared using a Biosearch 8600 DNA synthetizer" 'I: (a) 5'-GGA-RNA preparation.
Oligonucleotides. Amplified samples were sizeseparated by gel electrophoresis using 3% Nusieve, 1% SeaKem (FMC BioProducts, Rockland, ME) gel. A 123-bp DNA ladder (Bethesda Research Laboratories) was used as a size marker. Gels were stained with ethidium bromide and photographed. Amplified cDNA fragments were transferred electrophoretically to a Nytran nylon membrane (Schleicher & Schuell, Keene, NH). Antisense oligonucleotides complementary to the B2/A2 splice and B3/A2 splice were end-labeled using tdt (15 U/pL) (Bethesda Research Laboratories), "P-dATP-Cordycepin (DuPont/New England Nuclear, Wilmington, DE), and l to 2 x lo6 cpm/mL added to the hybridizing solution for each membrane. Following 12 to 16 hours of hybridization at 42"C, membranes were washed. After initial hybridization with the B2/A2 probe, all membranes were stripped and reprobed with the B3/A2 probe.
GCT-GCA-GAT-GCT-GAC-
To test for contamination, we included several positive (K562: control for B2/A2 splice; cells from a patient with known breakpoint 5' to bcr exon 3: control for B3/A2 splice) and negative (Raji cells and a reagent control consisting of all reagents except RNA) controls. To interpret negative results, RNA samples were subjected to PCR using probes for P-actin mRNAZ"" using the following oligonucleotides: (g) 5 '-TAC-CTC-ATG-AAG-ATCDetection of amplified fragments.
Controls.
CTC-A-3'; (h) 5'-C-AGG-ACA-CCG-TAG-GTG-CIT-3'; (i) 5'-
CCA-TCT-CIT-GCT-GCA-AGT-C-3 ' .
Sequence (9) is the 5' sense primer from exon 111, (h) is the 3' antisense primer from exon IV, and (i) is the internal probe representing an exon 111 antisense sequence. Amplification of P-actin mRNA was accomplished using conditions identical to the bcrlabl amplification, except that oligonucleotide (h) was used as primer for reverse transcription, oligonucleotide (8) added with Taq polymerase, and following electrophoresis and Southern transfer, the p-actin cDNA probed with oligonucleotide (i). The resulting amplified cDNA is 273 bp.
Statistics
Results of experimental points obtained from multiple experiments are reported as the mean 2 1 SEM. Significance levels were determined by two-sided Student's t-test.
RESULTS
Purified progenitor populations were obtained by depleting BMMNC of cells expressing myeloid, monocytic, B-lymphoid, T-lymphoid, and natural killer cell antigens by immunomagnetic depletion (lineage-negative). The lineagenegative cells were subsequently subjected to positive selection by four parameter FACS sorting of cells with lowlvery low horizontal light scatter properties and very low vertical light scatter properties, expressing high density of CD34 antigens and either expressing (referred to as DR' cells) or lacking (referred to as DR-cells) HLA-DR antigen (Fig l) ." The DR-and DR+ cell content of CML BMMNC was significantly lower than that of 10 normal individuals (Table 2 ). This was accompanied by an increase in more mature differentiated myeloid cells, which were depleted during the initial negative immunomagnetic selection step. The morphology of CML DR-cells is that of small lymphocyte-like blasts contaminated with small numbers of basophilic precursors, while CML DR' cells are larger blasts with multiple nucleoli.
To determine the number of committed clonogenic cells in CML DR-and DR' cells, we plated both cell fractions in short-term methylcellulose assay. The number of clonogenic cells present in the CML DR-population was similar to that found in the DR-fraction from normal individuals (Table 2) . However, the absolute number of DR-clonogenic cells in CML bone marrow (3.5 ? 1.3/106 CML BMMNC) was significantly lower than the absolute number of DR-clonogenic cells in normal bone marrow (58.3 ? 13.2/10h normal BMMNC, P = .004). The number of clonogenic cells present in the DR' population derived from CML bone marrow was similar to that found in normal DR' cells. As was seen for the DR-clonogenic cells present in CML bone marrow, the absolute number of DR' clonogenic cells in CML bone marrow (198.9 & 88/106 BMMNC) was significantly different than that in normal bone marrow (542 ? 52/106 BMMNC, P = .003). This lower absolute number of both DR-and DR' clonogenic cells recovered from CML bone marrow is possibly the result of the increase in more mature committed myeloid progenitors characteristic of CML.
We then evaluated the number of more primitive LT-BMC-IC present in either cell population by plating DRand DR' cell fractions on irradiated allogeneic normal bone marrow stroma. These cultures were then evaluated for the production of secondary clonogenic cells in the nonadherent supernatant and the adherent stromal layers over 8 consecutive weeks (Table 2 , Fig 2A through D) . Similar to normal DR-cells'" (Fig lB) , CML DR-cells (Fig  2A) are capable of inducing long-term hematopoiesis in LTBMC for at least 8 weeks. However, the generation of secondary clonogenic cells at week 5 or 8 in cultures initiated with CML DR-cells is less than that seen in cultures initiated with normal DR-cells (P = ,001). The absolute number of DR-LTBMC-IC in CML bone marrow (5.6 ? 2.9/106 CML BMMNC) was significantly lower than the absolute number of DR-LTBMC-IC present in normal bone marrow (126.2 +-9.78/106 normal BMMNC, P = .OOO). In contrast to normal DR' cells (Fig 2D) , which contain only few LTBMC-IC, CML DR' cells (Fig 2C) contain significantly greater numbers of LTBMC-IC ( P < .001), which sustain growth of clonogenic cells in LTBMC for at least 8 weeks. Likewise, the absolute number of DR' LTBMC-IC present in CML bone marrow (25.9 ? 9.1/106 CML BMMNC) was significantly greater than that of normal bone marrow (5.03 f l.l/lOh normal BMMNC, To determine the clonal origin of primitive progenitors in CML DR-and DR' cells, we plated DR-and DR' cells from CML bone marrow on irradiated allogeneic stroma derived from normal donors of the opposite sex. These LTBMC cultures were killed at week 1, 5, or 8 and recovered cells plated in methylcellulose culture. Resultant secondary colonies were plucked and examined for the presence of the Ph' and expression of bcrlabt mRNA.
Cytogenetic studied4 of pooled, plucked secondary colonies obtained from LTBMC initiated with DR-cells of six CML patients (patients 1 to 6) demonstrated only normal karyotype at week 1, 5, and 8 of culture (Table 3) . The benign or malignant nature of these clonogenic cells was confirmed by molecular genetic analysis of PCR-amplified total cellular mRNA of single colonies plucked at week 5 for patients 3,5, and 6 and at week 8 for patient 4 ( Table 3 , Fig 3) . All secondary colonies derived from LTBMC initiated with DR-cells from patients 3, 4, 5, and 8 failed to express the bcrlabl mRNA, but contained amplifiable @-actin mRNA. In contrast to the previous six patients, all but one secondary colonies derived from LTBMC initiated P = .02). with DR-cells from patient 7 contained the Ph', and eight of nine analyzed colonies recovered at week 5 expressed the bcrlabl mRNA. (right) cells from the bone marrow of patient 3. The amplified cDNA was electrophoretically size-separated, transferred t o nylon paper, and ethidium-stained. The cDNA was then probed using radiolabeled probes as described (not shown). The DR-and DR' colonies were judged t o express the bcrlabl mRNA if the colonies also had amplifiable p-actin (bottom). The size of the amplified cDNA from the DR' colonies was consistent with the bcr breakpoint location and the splicing pattern seen in the bone marrow of patient 3.
only Phi-positive metaphases (Table 3) , and this at week 1, 5, and 8 of culture. All analyzed secondary colonies from 5-or 8-week-old LTBMC initiated with DR' cells of patients 3,4,5, and 7 also expressed the bcrlabl mRNA (Table 3 , Fig  3) . The bcrlabl splicing pattern demonstrated in the amplified mRNA from these colonies was consistent with the bcr breakpoint location and the splicing pattern seen in bone marrow from the same patient. In contrast to the previous patients, secondary colonies recovered at week 5 from LTBMC initiated with DR' cells from patient 6 demonstrated only normal karyotype and only four of 10 analyzed colonies contained bcrlabl mRNA, while all but one analyzed colonies recovered at week l of LTBMC initiated with DR' cells contained the Phl.
DISCUSSION
This study demonstrates that coexistent benign, primitive hematopoietic progenitors can be separated from their malignant counterparts in CML bone marrow by differences in cell surface antigen expression. These benign primitive progenitors are phenotypically similar to very primitive hematopoietic progenitors isolated from the bone marrow of normal individuals. Such cells are morphologically small blasts, exhibit CD34 antigen expression, and lack detectable levels of antigens associated with T-cell, B-cell, or myeloid lineage, as well as HLA-DR antigens. These benign DR-primitive progenitors from CML bone marrow proliferate in stroma-dependent cultures for at least 8 weeks. This population can be distinguished from malignant Ph'-positive primitive progenitors with long-term in vitro hematopoietic repopulating capacity by differences in cell surface antigen expression (HLA-DR expression).
The number of secondary clonogenic progenitors cultured in LTBMC initiated with CML DR-cells is significantly lower than that of LTBMC initiated with normal DR-cells. This is unlikely to be the result of more extensive The absolute number of LTBMC-IC, measured as secondary clonogenic cells in LTBMC initiated with DR-cells multiplied by the percent recovery of cells in the DRfraction, present in CML bone marrow mononuclear cells is significantly lower than that in normal bone marrow. This may be the result of a more quiescent state of benign primitive progenitors in CML bone marrow compared with primitive progenitors found in normal bone marrow. Alternatively, these observations may suggest that the number of benign primitive progenitors in CML bone marrow is significantly lower than that of normal bone marrow. Additional studies in which the absolute number of LTBMC-IC, rather than LTBMC-IC-derived secondary clonogenic cells, is evaluated will be needed to resolve this question.
Previous studies have demonstrated that growth of progenitors from CML bone marrow ex vivo in long-term marrow culture results in the selection of coexistent benign Ph'-negative progenitors."' In these studies, clonogenic and granulocytic cells recovered from LTBMC initiated with CML BMMNC exhibit the Ph' and bcrlabl gene rearrangement through week 4 to 5 of culture, whereas cells recovered after week 4 to 5 contained only Phi-negative nonclonal progenitors. 6 In the present study, we demonstrate that CML DR-cells give rise exclusively to benign Ph'-negative clonogenic progeny in both nonadherent and adherent fractions of LTBMC culture as early as day 7 after initiation of the culture. Moreover, culture of the DR' fraction of bone marrow resulted in the persistent generation of malignant Ph'-positive secondary clonogenic cells through week 8 of culture. These data indicate that the malignant Phi-positive clone derived from the bone marrow of these CML patients can persist in LTBMC when cultured separately. The presence of exclusively benign clonogenic cells as early as 7 days after initiation of the ex vivo culture in LTBMC initiated with CML DR-cells is therefore unlikely to be the result of an in vitro selection attributable to the LTBMC culture itself, but of the selection by phenotype performed before culture in LTBMC. Analysis of pooled colonies for the presence of the Phl chromosome may skew the results in the direction of more highly mitotically active colonies in the pool, and may decrease the sensitivity to detect nondividing, possibly malignant, clonogenic cells. Similarly, evaluation of a relatively small number of single plucked second generation colonies (four to 11 colonies per patient) for the presence of the bcrlabl gene rearrangement may not detect a minor population of malignant colonies. However, the consistently benign genotype of the DR-population in six of seven patients indicates that selection of the DR-fraction from CML bone marrow results in the purification of a population of exclusively benign primitive progenitors.
The presence of benign secondary clonogenic cells in LTBMC initiated with DR' cells from patient 6 at week 5 of LTBMC culture may be the result of the long-term culture itself, rather than the initial selection process. Patient 6 differed from the other patients in that he was recovering from severe bone marrow aplasia induced by hydroxyurea therapy. Cytogenetic studies of freshly aspirated bone marrow cells obtained at the time of study showed a predominance (67%) of Ph'-negative cells. The DR' cells from this patient failed to sustain generation of secondary clonogenic progenitors in LTBMC for more than 5 weeks. The benign Phi-negative progenitors present in the DR' cell population may therefore represent an unusually expanded population of less primitive benign progenitors with limited self-renewing capacity.
The only patient in whom the DR-fraction of bone marrow cells contained malignant Phi-positive progenitors is patient 7. Clinically, patient 7 differs from the other six patients in that she was treated with interferon-a until 3 months before study and with hydroxyurea until the day of study. Recent studies have demonstrated that interferon-a can restore the impaired adhesion of CML progenitors to the bone marrow microenvironmentx and may render these progenitors susceptible to negative regulatory signals produced by marrow stromal cells, which maintain the stem cell reserve in a quiescent ~tate.'~.'~ Moreover, hydroxyurea inhibits ribonucleotide reductase, resulting in depletion of the deoxyribonucleotide pools required for DNA synthesis" and inhibition of cell replication. This prevents malignant CML progenitors from cycling and may decrease their expression of cell surface activation antigens, such as HLA-DR. '4,29 Multiple studies have addressed the expression of HLA-A, B, C, and D antigens in human malignancie~?~.~~ De novo or increased expression of class I1 HLA antigens on malignant cells has been observed in a variety of tum0rs.3'"~ It has been speculated that downregulation or upregulation of HLA-class I or I1 expression may be a common feature of malignant transformation mediated by oncogenes. Class I HLA antigen expression can be influenced by oncogenic viral infection or oncogene transfection into normal cells with resultant cell tran~formation.3~ HLA-DR expression is increased after malignant transformation of melanocytes with ras oncogenes. 34 The increased expression of HLA-DR antigens on malignant CML primitive progenitors could therefore be caused by dysregulation of the HLA-DR gene or its expression-regulating genes by the bcrlabl gene product. Similar to what we observe here for CML DR+ cells, we demonstrated previously that the less primitive DR' cells derived from normal human bone marrow fail to adhere to irradiated stromal layers? HLA-DR expression on the malignant DR+ cell fraction could therefore be a reflection of a more differentiated stage of these progenitors compared with the benign DR-fraction in normal or CML bone marrow. This would be consistent with the observation that more differentiated cells within the same lineage often express greater density of HLA-DR antig e n~.~"~~ However, the observation that such malignant DR' progenitors give rise to sustained in vitro generation of clonogenic progenitors indicates that benign DR-and
